Pluri Inc. Increase (Decrease) in Accounts and Other Receivables
Pluri Inc. (PLUR) reported Increase (Decrease) in Accounts and Other Receivables of -$149.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-09-10
- Pluri Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was -$12.00K, a 120.69% decline year-over-year.
- Pluri Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$70.00K, a 284.21% decline year-over-year.
- Pluri Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was -$125.00K, a 256.25% decline year-over-year.
- Pluri Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was $58.00K, a 123.08% increase year-over-year.
- Pluri Inc. increase (decrease) in accounts and other receivables for fiscal 2026 was -$149.00K, a 173.76% decline from fiscal 2025.
- Pluri Inc. increase (decrease) in accounts and other receivables for fiscal 2025 was $202.00K.
- Pluri Inc. increase (decrease) in accounts and other receivables for fiscal 2024 was -$76.00K.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | -$82.00K derived: sum of 2 quarters · filed 2026-09-10 | -$207.00K derived: sum of 3 quarters · filed 2026-09-10 | -$149.00K 10-K · filed 2026-09-10 |
| 2026-03-31 | -$70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | -$195.00K derived: sum of 2 quarters · filed 2026-05-14 | -$137.00K 10-Q · filed 2026-05-14 | -$79.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | -$125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$67.00K 10-Q · filed 2026-02-12 | -$9.00K derived: sum of 3 quarters · filed 2026-09-10 | $29.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-12 | $116.00K derived: sum of 2 quarters · filed 2026-09-10 | $154.00K derived: sum of 3 quarters · filed 2026-09-10 | $234.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $96.00K derived: sum of 2 quarters · filed 2026-09-10 | $176.00K derived: sum of 3 quarters · filed 2026-09-10 | $202.00K 10-K · filed 2026-09-10 |
| 2025-03-31 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $118.00K derived: sum of 2 quarters · filed 2026-05-14 | $144.00K 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $106.00K 10-Q · filed 2026-02-12 | ||
| 2024-09-30 | $26.00K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$76.00K 10-K · filed 2025-09-17 | |||
| 2023-12-31 | -$94.00K 10-Q · filed 2025-02-11 | |||
| 2020-03-31 | $124.00K 10-Q · filed 2020-05-11 | |||
| 2019-03-31 | -$227.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |